May Daher
Associate Director, Translational Research, Institute for Cell Therapy Discovery & Innovation · University of Texas M D Anderson Cancer Center
Credentials: · ·
History
- 2011–2014
Internal Medicine
- 2006–2010
Doctor of Medicine
Research
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
New England Journal of Medicine · 2020 · 1,804 citations
Nature Medicine · 2024 · Co-first of 36 authors · 428 citations
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Cancer Cell · 2022 · 318 citations
- KR
59 papers
48 papers
38 papers
20 papers
17 papers · 5 as a fellow
- AO
16 papers
16 papers · 2 as a fellow
- HS
15 papers · 12 as a resident
Grants
- 2026–2031
Advancing TGFβ-Resistant CAR-NK Cell Therapy for Acute Myeloid Leukemia
National Cancer Institute · R01
Contact PI · $387.2K · University of Tx Md Anderson Can Ctr
- 2025–2029
Advancing Next-Generation CAR-NK Therapies Targeting CD5 Positive T Cell Malignancies to the Clinic
National Cancer Institute · R01
PI · $1.8M · University of Tx Md Anderson Can Ctr
- 2023–2028
Next Generation Engineered NK Cells for Lymphoma Patients After CD19 CAR-T Cell Failure.
National Cancer Institute · R01
Contact PI · $1.5M · University of Tx Md Anderson Can Ctr
Clinical trials
- 2023–2026
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center